RxDoctor Payments Data

Raymond Clifford, MD

Ophthalmology · Berlin, MDNPI 1578963310

Payments from drug & device makers

$407in general payments, 2019–2025

Across 10 payments — averaging $40.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$121
  • Alcon$118
  • AbbVie$95
  • Dompe US, Inc.$31
  • Tarsus Pharmaceuticals, Inc.$30
  • Novartis$12

What the payments were for

  • Food & beverage$32780%
  • Education$8020%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$407 in reported general payments places this provider in the 30th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$1,299,305
Medicare patients
1,612
Services billed
18,021

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine49$44,989
Prednisolone Acetate529$25,739
CombiganBrimonidine Tartrate/Timolol68$22,181
XiidraLifitegrast17$12,417
LumiganBimatoprost22$12,346
MoxifloxacinMoxifloxacin Hcl535$11,587
Cyclosporine20$8,901
RocklatanNetarsudil Mesylat/Latanoprost25$8,718
Ketorolac Tromethamine542$8,246
Fluorometholone92$5,737
Latanoprost453$5,713
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol28$3,871
Travoprost20$3,524
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat210$3,379
Loteprednol Etabonate25$3,134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan$95$79,515139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Berlin

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →